Page 8 - Kronos Bio News Today

/PRNewswire/ -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider...

Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately o...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Posters include preclinical data on SYK inhibition in combination with targeted agents suggesting evidence of preclinical anti-tumor activity in acute...

SAN MATEO, Calif. and CAMBRIDGE, Mass., June 01, 2022 -- Kronos Bio, Inc. , a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced... | June 1, 2022

The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services.

Posters include preclinical data on SYK inhibition in combination with targeted agents and demonstrate preclinical anti-tumor activity in acute myeloid leukemia Additional presentations... | May 12, 2022

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the Measurable residual disease Partnership and Alliance in Acute...

Clovis Oncology (NASDAQ:CLVS – Get Rating) and Kronos Bio (NASDAQ:KRON – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk. Earnings & Valuation This table compares Clovis Oncology and […]

Athira Pharma is circling the wagons and urging shareholders to reject investor Richard Kayne's calls for a management change.